Commercial marketing data lives in one system, real-world evidence in another, and payer data in a third – none of them talk to each other. We build the connective layer so clinical milestones and commercial traction show up on the same page, with the compliance controls generic marketing platforms don't have.
The Problem
Three Systems, Zero Connection
HCP engagement sits in your CRM, DTC campaign data sits in an ad platform, and patient support enrollment sits in a hub services portal that nobody outside operations logs into. Nobody owns the join. Every board deck becomes a manual export-and-merge exercise the week before the meeting, and the numbers rarely agree with what medical affairs is reporting.
Commercial Data Has No Clinical Context
You can tell your board that DTC spend is up and website conversions are up, but you can't tell them whether that traffic is converting into enrolled patients who stay on therapy. Without linking campaign data to real-world evidence and adherence signals, marketing looks like activity instead of outcome, and that's the exact gap investors probe for at every update.
Compliance Sensitivity Breaks Off-the-Shelf Tools
Patient support enrollment and RWE data carry HIPAA-adjacent sensitivity that consumer marketing analytics platforms were never built to handle. Teams either avoid connecting the data at all, which keeps everyone blind, or they connect it manually through spreadsheets passed over email, which creates a compliance exposure nobody flagged until legal asks who has access.
Reporting Cadence Doesn't Match Decision Cadence
Market access and medical affairs report on a quarterly or per-milestone cycle. Commercial marketing reports monthly or weekly. When the board asks how a Phase 3 readout is tracking against DTC awareness lift, the honest answer is usually 'we'll pull that together for next time' because the reporting rhythms were never built to intersect.
How We Help
We start with an audit, not a dashboard build. Before we touch a single visualization, we map every system that touches commercial or patient data: the CRM tracking HCP engagement, the ad platforms running DTC campaigns, the hub services vendor handling patient support enrollment, and whatever RWE or claims data your medical affairs team is sitting on. Most companies are surprised by how many of these systems exist and how few of them export in a compatible format.
From there we build a data model, not a tool purchase. The goal is a single source of truth that maps commercial activity to clinical and access milestones without moving patient-level data anywhere it shouldn't be. We work inside your existing compliance boundaries – if data can't leave a HIPAA-covered environment, we build the connection there, not by exporting it into a marketing platform that was never reviewed for that use.
Execution happens in phases. First we connect the two or three data sources causing the most pain right now, usually DTC performance and patient support enrollment, since that pairing tells you whether campaigns are actually converting into enrolled patients. Second we layer in HCP engagement data so you can see the full funnel from prescriber awareness to patient enrollment. Third, where RWE or payer data is available, we connect adherence and access signals so commercial performance has clinical grounding.
Measurement is built around the questions your board actually asks: is DTC spend converting into enrolled, adherent patients, and how does that trend against clinical milestones. We're not building a vanity dashboard with fifty metrics nobody checks. We're building the five or six numbers that tell the real story, updated on a cadence that matches your board meeting schedule instead of whatever cadence each underlying tool defaults to.
We also build the governance layer most companies skip: who can see patient-level data, who sees only aggregates, and how that access is logged. This isn't optional in biotech. Getting it wrong is a compliance incident, not a marketing inefficiency.
The deliverable isn't a slide. It's a live system your team owns and updates, with documentation so it survives a personnel change instead of dying the day the person who built it in a spreadsheet leaves.
What we deliver
- Data source audit – a full map of every system touching commercial, medical affairs, and market access data, with compliance flags on each connection point
- Unified reporting model – one data structure joining HCP engagement, DTC performance, and patient enrollment without moving restricted data outside its compliance boundary
- Board-ready dashboard – the five to six metrics that connect commercial traction to clinical and access milestones, updated on your board's actual cadence
- Access governance documentation – who sees what, logged and reviewable, built to survive an audit rather than explain one after the fact
If your DTC spend and your patient enrollment numbers live in different systems, you don't have a marketing funnel – you have two disconnected guesses that happen to sit next to each other in a board deck.
Our Methodology
We run this as a 90-day sprint because biotech data problems don't get solved by installing a dashboard tool – they get solved by deciding, system by system, what can connect and what has to stay walled off. Days 1-30 are the audit: every data source gets mapped, every compliance boundary gets identified, and we agree with your legal or compliance lead on what's connectable before we build anything.
Days 31-60 are the build. We connect the highest-value pairing first, almost always DTC or HCP engagement data against patient support enrollment, since that's the link that turns activity metrics into outcome metrics. We test the join against real numbers your team already has, not sample data, so the first version is trustworthy from day one.
Days 61-90 are refinement and handoff. We tune the dashboard against what your board actually asks in meetings, document the governance model, and train whoever on your team owns reporting going forward. By day 90 you have a system, not a one-time deliverable that decays the next quarter.
How We Work
Weeks 1-4: discovery and audit. We interview your commercial, medical affairs, and market access leads separately, because they each see a different slice of the data problem and rarely compare notes. We come out of this phase with a data source map and a compliance-cleared connection plan.
Weeks 5-8: build. We connect the priority data pairing and stand up the first version of the dashboard. You'll see working output by week 6, not a wireframe – we'd rather you react to something real than approve a mockup.
Weeks 9-12: refine and hand off. We adjust the metrics based on what actually gets used in board and leadership meetings, finalize governance documentation, and train your internal owner. Our team is a strategist plus a data/analytics lead, embedded on a weekly call with your commercial and medical affairs stakeholders.
After the 90 days, most clients move to a lighter monthly retainer for maintenance and expansion as new data sources come online – a new hub services vendor, a new RWE partnership, a new market access deal. Typical engagement pricing runs $15,000 to $40,000 per month depending on the number of systems involved and the depth of the compliance review required.
- A board reporting process that connects commercial activity to clinical and access milestones instead of presenting them as unrelated updates
- A defensible, documented data governance model that reduces compliance exposure around patient and RWE data
- An internal team that owns and can maintain the reporting system after the engagement ends, instead of depending on an outside vendor indefinitely
If your biotech & pharma company needs data, reporting & analytics leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does this typically cost?
Most engagements run $15,000 to $40,000 per month, scaled to how many systems need to connect and how much compliance review the data requires. A company connecting DTC and patient enrollment data only sits at the lower end. A company also integrating RWE, payer data, and HCP engagement across multiple brands sits higher. We scope this in the first call once we know what systems you're running.
How long until we see a working dashboard?
You'll see a working first version by week 6 of the 90-day sprint, built on your real data rather than a mockup. The first 30 days go to the audit and compliance mapping because skipping that step is how companies end up with a dashboard that has to be rebuilt once legal flags a data access issue.
Will this require our internal team's time, or do you run it independently?
It requires time, but not full-time involvement. We need your commercial, medical affairs, and market access leads for interviews in weeks 1-4 and for review checkpoints during the build. By the end of the engagement, someone on your team is trained to own and update the system, which is the point – we're not building something you depend on us to run forever.
How is this different from hiring a marketing analytics agency?
Most marketing analytics agencies build dashboards for DTC and paid media performance and stop there. They don't have a framework for joining that data with medical affairs or market access data, and they generally aren't equipped to handle the compliance review that patient-adjacent data requires. We build the connective layer across all three functions, with the governance work included, not bolted on afterward.
How do you measure ROI on this kind of engagement?
ROI here isn't a single number – it's measured by whether your board reporting process changes. Before: manual spreadsheet merges, numbers that don't reconcile across functions, and no visibility into whether commercial spend converts into enrolled patients. After: a live system answering that question on a fixed cadence. The value shows up in faster, more confident board conversations and in catching commercial underperformance months earlier than a quarterly manual review would.
What kind of biotech or pharma company is the best fit for this?
Series A to growth-stage companies with at least one commercial or near-commercial asset, where marketing, medical affairs, and market access already exist as separate functions with separate data. If you're pre-commercial with no DTC or patient support program yet, this engagement is premature – come back once there's real commercial data to connect.
